Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype by David A. Sallman et al.
June 2016 | Volume 6 | Article 1511
Review
published: 16 June 2016
doi: 10.3389/fonc.2016.00151
Frontiers in Oncology | www.frontiersin.org
Edited by: 
Carmen Aanei, 
University Jean Monnet 
Saint-Etienne, France
Reviewed by: 
Rebecca Leigh Schmidt, 
Upper Iowa University, USA  
Claude Lambert, 
University Hospital 
Saint-Etienne, France
*Correspondence:
Alan List  
alan.list@moffitt.org
Specialty section: 
This article was submitted to 
Hematology Oncology, 
a section of the journal 
Frontiers in Oncology
Received: 30 March 2016
Accepted: 03 June 2016
Published: 16 June 2016
Citation: 
Sallman DA, Cluzeau T, Basiorka AA 
and List A (2016) Unraveling the 
Pathogenesis of MDS: The NLRP3 
Inflammasome and Pyroptosis 
Drive the MDS Phenotype. 
Front. Oncol. 6:151. 
doi: 10.3389/fonc.2016.00151
Unraveling the Pathogenesis of MDS: 
The NLRP3 inflammasome and 
Pyroptosis Drive the MDS Phenotype
David A. Sallman1, Thomas Cluzeau2,3,4,5, Ashley A. Basiorka6 and Alan List1*
1 Malignant Hematology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA, 2 Hematology 
Department, Centre Hospitalier Universitaire of Nice, Nice, France, 3 Faculty of Medicine, University Nice Sophia Antipolis, 
Nice, France, 4 Mediterranean Center of Molecular Medicine, INSERM U1065, Nice, France, 5 French Group of 
Myelodysplasia, Paris, France, 6 Cancer Biology Ph.D. Program, H. Lee Moffitt Cancer Center and Research Institute, 
University of South Florida, Tampa, FL, USA
Myelodysplastic syndromes (MDS) are characterized by bone marrow cytological dys-
plasia and ineffective hematopoiesis in the setting of recurrent somatic gene mutations 
and chromosomal abnormalities. The underlying pathogenic mechanisms that drive 
a common clinical phenotype from a diverse array of genetic abnormalities have only 
recently begun to emerge. Accumulating evidence has highlighted the integral role of the 
innate immune system in upregulating inflammatory cytokines via NF-κB activation in the 
pathogenesis of MDS. Recent investigations implicate activation of the NLRP3 inflam-
masome in hematopoietic stem/progenitor cells as a critical convergence signal in MDS 
with consequent clonal expansion and pyroptotic cell death though caspase-1 matura-
tion. Specifically, the alarmin S100A9 and/or founder gene mutations trigger pyroptosis 
through the generation of reactive oxygen species leading to assembly and activation 
of the redox-sensitive NLRP3 inflammasome and β–catenin, assuring propagation of 
the MDS clone. More importantly, targeted inhibition of varied steps in this pathway 
restore effective hematopoiesis. Together, delineation of the role of pyroptosis in the 
clinical phenotype of MDS patients has identified novel therapeutic strategies that offer 
significant promise in the treatment of MDS.
Keywords: MDS, pyroptosis, inflammasome, NLRP3, S100A9, TLR
iNTRODUCTiON
Myelodysplastic syndromes (MDS) represent a heterogeneous group of clonal hematopoietic 
neoplasms hallmarked by ineffective erythropoiesis, bone marrow (BM) dysplasia, and risk 
of transformation to acute myeloid leukemia (AML). In depth molecular characterization has 
shed significant insight into the molecular architecture of this disease that impacts diagnosis 
and prognosis, while illustrating the genetic complexity of these malignancies. Specifically, the 
molecular heterogeneity in MDS involves mutations of splicing gene machinery, epigenetic regula-
tion, differentiation, and cell signaling. How these seemingly diverse perturbations result in a 
common clinical and hematological phenotype remains unexplained. Recent investigations have 
identified a critical role of innate immune and inflammatory signaling in the development of MDS, 
as well as provide a link between the genetic heterogeneity and the myelodysplastic phenotype. 
More importantly, deciphering the key biological features of this disease offers the opportunity 
FiGURe 1 | TLR signaling governs multiple cellular processes through a complex signaling network. A simplified schematic of TLR signaling is presented. 
(A) The majority of the TLRs reside in the plasma membrane (with the exception of TLR3, TLR7–9). Following receptor ligation, a number of signaling adaptor 
proteins will be recruited, including MyD88, TIRAP, TRAM, and TRIF. Depending on the particular stimulus, certain TLRs will become activated, resulting in 
recruitment of specific adaptor proteins, kinases, and ubiquitin ligases that will help propagate signaling. (B) Through interaction with MyD88, the serine/threonine 
kinase IRAK4 will be recruited. Subsequently, IRAK1 and IRAK2 will be activated. (C) Autoubiquitination of TRAF6 allows for recruitment of the IKK complex (IKKα, 
IKKβ, and IKKγ/NEMO). Phosphorylation of IKKβ by TAK1 allows for phosphorylation of NF-κB, thereby targeting Ikβ proteins for degradation. Liberated NF-κB can 
enter into the nucleus and direct transcription. (D) MyD88 and IRAK join to form a large multiprotein complex including the E3 ubiquitin ligase TRAF6. 
(e,F) Activation of TAK1 and MEKK1 result in a signaling cascade, leading to the activation of MAPK signaling and modulation of gene expression.
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for novel, biologically rational therapeutic strategies to target the 
underlying disease pathogenesis.
TLR SiGNALiNG AND ROLe iN MDS
Antigen recognition by the innate immune system is accomplished 
via the interaction of pathogen-associated molecular patterns 
(PAMPs) with pattern-recognition receptors (PRRs). Toll-like 
receptors (TLRs) represent the most important members of the 
PRR family, and activation of TLRs triggers multiple cellular 
processes via a complex signaling cascade, as shown in Figure 1 
(1, 2). In humans, 10 TLRs (TLR 1–10) have been identified, and 
each TLR is composed of a leucine-rich ectodomain, a transmem-
brane domain, and a toll-interleukin 1 receptor (TIR) domain. 
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The TIR domain is responsible for signal transduction, which 
occurs through the recruitment of specific adaptor molecules, 
including myeloid differentiation primary response 88 (MyD88), 
TIR-domain-containing adaptor protein (TIRAP), TIR-domain-
containing adapter-inducing interferon-β (TRIF), and the TRIF-
related adaptor molecule (TRAM) (3). MyD88 is utilized by all 
TLRs with the exception of TLR3, which employs TRIF. Together, 
TLR signaling occurs either via MyD88-dependent pathways 
leading to the activation of nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) and mitogen-activated pro-
tein kinases (MAPKs) with induction of inflammatory cytokines, 
or through TRIF-dependent induction of type 1 interferon (IFN) 
through the activation of IFN regulatory factor 3 (IRF3) (2). TLR4 
is activated by an array of ligands, including lipopolysaccharide 
(LPS), which triggers both MyD88 and TRIF-dependent signaling 
through interaction with the specific adaptor molecules TIRAP 
and TRAM, respectively. Of interest, TLR4-mediated induction 
of inflammatory cytokines requires activation of both pathways, 
which is distinct from all other TLRs (4, 5). MyD88-dependent 
activation of NF-κB and additional effectors occurs through the 
sequential activation of IL-1 receptor-associated kinases (IRAKs). 
Specifically, ligand-induced dimerization of TLR results in IRAK4 
recruitment and activation followed by the activation of IRAK1 
and IRAK2 (6). IRAK then dissociates from the receptor complex 
to create a large multiprotein complex involving the E3 ubiquitin 
ligase TNF receptor-associated factor-6 (TRAF6), the mitogen-
activated kinase kinase kinase family member, TGF-β-activated 
kinase (TAK)-1, IκB kinase (IKK), TAB2/TAB3, and NEMO, 
respectively (7, 8). TAK1 phosphorylation of IKK-β triggers the 
phosphorylation of NF-kB-bound IκB proteins, targeting them 
for ubiquitin-dependent degradation and liberating NF-κB 
dimers to enter the nucleus.
Hematopoietic cytokines play an indispensable role in 
the maturation of myeloid precursor cells under steady state 
conditions and particularly during stress, such as infection 
and inflammation (9). Importantly, these cytokines have 
pleiotropic effects on hematopoietic cells, including regulation 
of proliferation, maturation, and activation. More recent inves-
tigations have shown that hematopoietic stem and progenitor 
cells (HSPCs) also harbor TLRs, including TLR4, which upon 
activation by LPS lead to HSPC proliferation. As HSPCs do not 
have intrinsic effector function, TLR activation plays a distinct 
role of localization to sites of infection/inflammation (e.g., 
lymph nodes) and the replenishment of effector cells (10, 11). 
Although previous understanding of HSPCs reasoned that their 
quiescent state resulted in protection from mutagenesis, recent 
work has highlighted that HSPCs have significant dependence 
on non-homologous end-joining DNA repair, and this process 
increases susceptibility to somatic mutations (12). In addition, 
innate immune-induced changes in the surrounding stroma, i.e., 
the mesenchymal cells, could potentially foster propagation of 
these clones, which would otherwise not have had a proliferative 
advantage (13, 14).
More recently, multiple components of the TLR signaling 
cascade have been associated with MDS (Figure 2). Specifically, 
TLR4 is upregulated in HSPCs of MDS patients and directly 
correlates with annexin-V positivity in BM mononuclear cells 
(BM-MNC) and CD34+ cells (15). In MDS patients, particularly 
in MDS with deletion of 5q (del(5q)), TRAF6 is overexpressed 
owing to haploinsufficiency of microRNA-145 and microRNA-
146a, negative regulators of TRAF6 (16). In addition, TRAF6 is 
also important in cell survival signaling of MDS HSPCs. IRAK1, 
the adaptor kinase activated upon TLR4 stimulation, is overex-
pressed in MDS progenitors (17, 18). Of therapeutic importance, 
IRAK 1/4 inhibition and/or RNA interference (RNAi) suppres-
sion of IRAK1 was selectively cytotoxic to MDS HSPCs without 
consequence to normal CD34+ cells (18). As  IRAK inhibitor 
therapy was shown to induce BCL-2 expression, suggesting a 
potential resistance mechanism, Rhyasen and colleagues provide 
initial evidence to support combination therapy of an IRAK 
inhibitor with a BCL-2 antagonist in both in  vitro and in  vivo 
models of MDS.
iNFLAMMATORY MeDiATiORS AS A 
DRiveR OF MDS PATHOGeNeSiS 
THROUGH MODULATiON OF THe BM 
MiCROeNviRONMeNT
In addition to PAMPs, damage-associated molecular patterns 
(DAMPs) or alarmins are molecules that are released during 
inflammation or cell death, which can modulate the innate 
immune system through TLR signaling, particularly TLR4 (19). 
Specifically, more recent work has highlighted that S100A8 and 
S100A9 are endogenous ligands of TLR4 and primarily exist as 
a heterodimeric complex, calprotectin, leading to the induction 
of an inflammatory response through autocrine and paracrine 
mechanisms (20). Previously, S100A8/A9 levels have been found 
to not only be elevated in inflammatory diseases but also play 
a unique role in the underlying pathogenesis of these diseases 
(20,  21). S100A8/A9 has been implicated in tumor promotion 
including colon cancer cell proliferation, where it also provides 
a plausible mechanism for colitis-associated colon cancer initia-
tion and progression (22). How this inflammatory mechanism is 
linked to innate immunity and cancer progression was unclear 
until recent investigations. Specifically, Cheng and colleagues 
demonstrated in vivo that this complex is of paramount impor-
tance for tumor progression through the induction of myeloid-
derived suppressor cells (MDSCs), which lead to the suppression 
of antitumor immunity (23). Of interest, MDSCs not only 
respond to but also produce S100A8/S100A9, leading to autocrine 
stimulation that is extinguishable by antibody neutralization (24).
Although a pro-inflammatory state leading to chronic 
immune stimulation and hematopoietic senescence has been 
linked to MDS (25), the underlying mechanisms relating to 
this pathogenic process have only been recently advanced. Of 
note, we have demonstrated that polyclonal MDSCs (CD33+/
Lin−/HLA−DR−) are significantly expanded in the BM of MDS 
patients. As shown in Figure  2, this expansion is mediated 
through S100A9 ligand activation of CD33, leading to production 
of the suppressive cytokines interleukin-10 (IL-10) and transform-
ing growth factor-β (TGF-β) (26). This immune suppressive 
mechanism occurs through the immunoreceptor tyrosine-based 
inhibition motif (ITIM) of CD33. Furthermore, S100A9 transgenic 
FiGURe 2 | A S100A9-pyroptosis circuit provokes phenotypes manifest in MDS. (A) Myeloid-derived suppressor cells (MDSCs) are markedly expanded in 
the BM of MDS patients. MDSCs produce and secrete S100A9, which functions to mediate progenitor cell death and also activates MDSCs in an autocrine 
manner. (B) S100A8/A9 binds both CD33 and TLR4, resulting in NLRP3 inflammasome assembly. Ligation of S100A8/A9 to TLR4 through the IRAK–TRAF6 axis 
results in NF-κB-mediated transcription and subsequent production of pro-inflammatory cytokines, like pro-IL-1β and -IL-18, along with inflammasome 
components. (C) S100A8/A9 promotes activation of NAPDH oxidase (NOX), which results in a dual function. First, NOX proteins generate ROS, which serve to 
active NLRs and trigger inflammasome assembly. Second, NOX-derived ROS result in the oxidation of nucleoredoxin (NRX), leading to its dissociation from 
disheveled (Dvl). Once dissociated, Dvl suppresses the β-catenin destruction complex, resulting in stabilization of β-catenin. This allows β-catenin to enter the 
nucleus and induce transcript of TCF/LEF-controlled genes, including cyclin-D1 and c-Myc, which are essential to self-renewal. (D) MDS-related gene mutations 
activate NF-κB and NLRP3 via NOX-generated ROS. (e) Formation of the NLRP3 inflammasome complex occurs as a consequence of ROS activation and DAMP 
signaling. Once activated, inflammasomes mediate conversion of pro-caspase-1 to its mature and catalytically active form. Active caspase-1 cleaves pro-IL-1β and 
pro-IL-18 to their mature forms. (F) Pyroptosis ensues with loss of membrane integrity resulting in the release of pro-inflammatory cytokines, ROS, and other 
intracellular contents into the extracellular milieu.
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mice manifest a phenotype similar to MDS patients with age-
dependent dysplastic changes and impaired hematopoiesis. 
Disruption of the S100A9/CD33/TLR4 circuit was able to restore 
effective hematopoiesis. Together, these data highlight that the 
BM microenvironment, and in particular MDSCs, are integrally 
linked to the pathogenesis of MDS. Although MDSC expansion 
has been found to occur in relation to senescence-dependent 
changes in the BM (27), this expansion alone is inadequate to 
induce an MDS phenotype and suggests that the upregulation 
of pro-inflammatory molecules, such as S100A9, could be the 
initiating event in the development of MDS. Additional evidence 
supporting this hypothesis is that the MDSCs derived from MDS 
patients are genetically distinct from the MDS clone and lack 
the corresponding somatic gene mutations and chromosomal 
abnormalities (26). As proof of this concept, recent elegant work 
has shown in deletion 5q MDS that ribosomal haploinsufficiency 
of Rps14 induces S100A8/A9, which is sufficient to block eryth-
roid differentiation in normal erythroid cells, while inactivation 
restores effective erythropoiesis in haplodeficient cells (28).
NLRP3 iNFLAMMASOMe ACTivATiON 
AND iNDUCTiON OF PYROPTOSiS 
UNDeRLY THe MDS PHeNOTYPe
Although the above studies clearly characterize the importance of 
inflammation and the innate immune system in the underlying 
pathogenesis of MDS, the precise mechanism of cell death was 
poorly understood. Although apoptosis and autophagy may play 
a role in MDS (see below), more recent work has demonstrated 
pyroptosis, a novel caspase-1-dependent pro-inflammatory cell 
death induced by DAMP activation of PRPs (29–31), to be the 
fundamental driver of HSPC death (Figure  2). Specifically, 
pyroptosis is executed through inflammasome formation, cyto-
solic, multiprotein complexes composed of nucleotide-binding 
domain and leucine-rich repeat pattern-recognition receptors 
(NLRs). NLR family pyrin domain-containing 3 (NLRP3) is 
the best characterized NLR and is activated in response to 
multiple DAMPs, leading to the recruitment of an apoptosis-
associated speck-like protein containing a caspase-recruitment 
5Sallman et al. Pyroptosis Drives the MDS Phenotype
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domain (ASC). Following recruitment to NLRP3, ASC binds 
 pro-caspase-1 leading to its cleavage and activation (32). Caspase-1 
activation results in multiple cellular processes, including nuclear 
condensation, conversion of precursors of the inflammatory 
cytokines interleukin 1β (IL-1β) and IL-18 to their active form, 
and pore formation leading to the influx of cations with cell 
swelling and osmotic lysis (32). Masters and colleagues provided 
an initial link of pyroptosis to hematopoiesis by demonstrating 
that inflammatory-mediated NLRP1a inflammasome activation 
by endotoxin resulted in pyroptosis of HSPCs and consequent 
cytopenias (30). In addition, intracellular S100A8/A9 heterodi-
mers form a scaffold for the membrane insertion and activation 
of NADPH oxidase to generate reactive oxygen species (ROS), 
which reciprocally induce NF-κB activation and inflammasome 
assembly leading to generation of pro-inflammatory cytokines 
(33). These authors show that, in particular, S100A9 is critical 
for NF-κB-mediated transcription of inflammasome components 
or “inflammasome priming” and is also a more potent inducer 
of cytokines than S100A8. Of importance, S100A9-induced lytic 
cell death provides a feed-forward amplification loop, whereby 
additional S100A9 is released along with other DAMPs, such as 
the TLR4 ligand high mobility group box-1 protein (HMGB1) 
and inflammasome components, including ASC (34, 35).
How an inflammatory mediated cell death could be integrated 
into a clonally heterogeneous-driven process had remained elu-
sive (Figure 2). To this end, we recently described a common 
pathway licensed by somatic mutations and/or DAMP signals 
to induce inflammasome activation and pyroptosis, resulting 
in the phenotypic features of MDS (36). Comparison of MDS 
BM-MNC to normal controls illustrated that pyroptosis, but 
not apoptosis, was profoundly primed as evidenced by marked 
upregulation of caspase-1 (~209-fold) and NLRP3 (~48-fold) 
without any difference in caspase-3 expression. In addition, 
fluorescent microscopy showed co-localization of caspase-1 
with NLRP3, confirming inflammasome assembly irrespective 
of the international prognostic scoring system (IPSS) risk cat-
egory. Pyroptosis execution, defined as active caspase-1+/active 
caspase-3+/annexin-V+ cells, was significantly increased in MDS 
HSPCs and their progeny compared to normal controls. Again, 
the percentage of pyroptotic cells was the predominant cause 
of cell death in comparison to apoptosis (active caspase-3/7+/
active caspase-1−/annexin-V+). In addition, BM plasma levels 
of S100A9 were significantly increased in MDS patients. 
Furthermore, treatment of normal BM-MNC with recom-
binant human S100A9 (rhS100A9) recapitulated the above 
MDS phenotype with activation of pyroptosis and induction of 
NLRP3 inflammasome formation, which was also observed in 
the S100A9 transgenic mouse model. Of particular importance, 
myelodysplastic HSPCs appear inherently primed for pyroptotic 
response to alarmins, such as S100A9, compared to their normal 
counterparts by virtue of overexpression of TLRs and down-
regulation of the primary negative regulator of inflammasome 
activity, the pyrin domain-only protein (POP)-1. Such TLR 
upregulation occurs in the setting of chronic and sustained TLR 
activation, driving myeloid hematopoietic skewing, loss of HSC 
quiescence, and telomere erosion (37, 38). Notably, pyroptotic 
cell death is characterized by the activation of plasma membrane 
cation channels, which trigger mitochondrial depolarization and 
cell swelling (39). MDS BM-MNC demonstrate unexplained 
macrocytosis. In  comparison to normal BM-MNC, we show 
that MDS specimens display rapid and sustained uptake of 
the cationic dye ethidium bromide, confirming cation channel 
activation in accordance with pyroptotic and MDS hallmarks. 
Transient receptor potential melastatin-2 (TRPM2), a cation 
channel found on hematopoietic cells, directs calcium influx and 
corresponding increases in cell volume following activation (40). 
As TRPM2 has been linked to NLRP3 activation (41), TRPM2 
may mediate the pyroptotic-driven cell swelling observed in 
MDS. More importantly, delineating the above processes has 
allowed for the development of novel therapeutic strategies. As 
an example, using a CD33/IgG chimera to neutralize S100A9 
reduced the pyroptotic fraction and improved in vitro colony-
forming capacity in primary MDS patient specimens. In our 
S100A9 transgenic mouse model, inflammasome inhibition using 
ICTA, an icariin derivative that inhibits NLRP3 inflammasome 
activation, was able to suppress pyroptosis and β-catenin activa-
tion, with corresponding restoration of effective hematopoiesis.
Previous studies have demonstrated that the superoxide-
generating NADPH oxidase (Nox) induces ROS production 
leading to inactivation of nucleoredoxin (NRX) in the β-catenin 
destruction complex, to activate the Wnt/β–catenin pathway 
(42). We investigated whether this pathway could be activated by 
S100A9 and/or genetic mutations to promote clonal expansion 
(36). Indeed, not only was ROS elevated and β-catenin markedly 
activated in MDS patient specimens compared to normal con-
trols, but also the treatment of normal BM-MNC with rhS100A9 
was able to recapitulate these findings. Activation of this 
ROS/β–catenin pathway along with inflammasome activation 
was induced by spliceosome mutations both in vitro and in in vivo 
murine models. Abrogation of this pathway by treatment with 
the antioxidant N-acetylcysteine (NAC), or specifically with the 
NAPDH oxidase (NOX) inhibitor diphenylene iodonium (DPI), 
prevented ROS production and β-catenin activation (i.e., nuclear 
β-catenin). Additionally, these findings were not specific to 
spliceosome mutations but were also observed in murine models 
driven by mutations of the epigenetic regulatory genes, including 
TET2 and ASXL1, indicating a common point of convergence by 
functionally diverse somatic gene mutations in MDS.
ADDiTiONAL CeLL DeATH 
MeCHANiSMS iN MDS
Although recent investigations have highlighted the critical 
role of pyroptosis in the pathogenesis of MDS as described 
above, additional cell death mechanisms may also contribute 
to the MDS phenotype (Figure 3). Apoptosis is well described 
and can be distinguished by two initiation pathways, the 
intrinsic and extrinsic mitochondrial pathways, which both 
converge on caspase-3 activation as the principal cell death 
executioner. The extrinsic pathway is dependent upon cell 
death receptors and its ligands, including tumor necrosis 
factor alpha (TNFα)/TNF receptor (TNF-R), Fas/Fas ligand, 
FiGURe 3 | Mechanisms of cell death involved in the pathogenesis of myelodysplastic syndromes (MDS). Apoptosis, pyroptosis, and autophagy all 
contribute to cell death in MDS. Apoptosis, a non-inflammatory cell death, can be triggered through an extrinsic or intrinsic pathway leading to effector caspase 
activation and apoptotic body formation. Pyroptosis is an inflammatory cell death mechanism, which is triggered by damage-associated molecular patterns 
(DAMPs), in particular S100A8/S100A9, leading to ROS production and inflammasome activation resulting in production of pro-inflammatory cytokines (i.e., IL-1β 
and IL-18) and caspase-1 activation with consequent cell lysis. Lastly, mitophagy, or the selective degradation of mitochondria through lysosomal recycling and an 
autophagic mechanism, leads to ROS production and can induce both apoptosis and pyroptosis.
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or TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL 
receptor (TRAIL-R) (43). Ligand activation of receptor will 
activate a signaling cascade that is also dependent on caspase-8 
activation (44). In contrast, the intrinsic pathway is dependent 
on mitochondria and BCL-2 members, inducing caspase-9 
activation (45).
Several studies have shown increased apoptosis in MDS 
BM-MNC (46, 47); however, these studies preceded recognition 
of pyroptosis and did not investigate caspase-1 activity. The 
specific apoptotic pathway leading to cell death in MDS patients 
appeared related to the stage of the disease, with activation of 
the extrinsic pathway predominantly in early-stage MDS versus 
intrinsic pathway activation during evolution of the disease. In 
early stages, an increase of apoptosis was attributed to an upregu-
lation of TNFα, Fas/Fas ligand, and TRAIL (48–50). All of these 
ligands belong to the extrinsic pathway of apoptosis and were 
linked to ineffective hematopoiesis and peripheral blood cyto-
penias. Moreover, inhibition of the extrinsic pathway restored 
effective hematopoiesis (51). During MDS progression, activation 
of the intrinsic pathway of apoptosis occurs, implicating BCL-2 
members. Whereas upregulation of proapoptotic proteins like 
Bak and Bax are demonstrable in lower-risk MDS, an increase 
in antiapoptotic proteins, including Bcl-2, Bcl-XL, and the Flice 
inhibitory protein (FLIP), was observed in high-risk MDS during 
progression to AML, due in part to NF-κB inhibition of apoptosis 
and cell proliferation (52, 53).
Autophagy is the catabolic process by which long-lived, 
superfluous, or damaged macromolecules and organelles are 
degraded by lysosomal hydrolases for recycling, thereby permit-
ting cells to survive starvation and stressful conditions (54, 55). 
The autophagy process, from phagosome formation to lysosome 
fusion, involves approximately 30 autophagy-related proteins 
(56). Both pharmacological and genetic evidence indicate that 
autophagy plays pleiotropic functions in hematopoietic cell 
homeostasis and leukemogenesis. Autophagy exerts either pro-
survival or tumor-suppressive functions, depending on both 
the context and the nature of the hematopoietic malignancy 
and initiating signal (57). Moreover, several autophagy genes, 
such as Beclin 1 and UV radiation resistance-associated gene 
(UVRAG), are now known to act as tumor suppressor genes 
(58). Given the cross talk between the autophagic and apoptotic 
pathways, autophagy has been implicated in cancer. Moreover, 
prolonged stimulation of autophagy can itself induce apoptosis 
(59). Autophagy also has a protective role through controlling 
oxidative stress as well as the accumulation of DNA damaging 
waste (57, 60). The selective removal of damaged mitochondria 
7Sallman et al. Pyroptosis Drives the MDS Phenotype
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by autophagy, called mitophagy, has been well studied in MDS 
(61, 62). Increased caspase-dependent apoptosis, ROS, and mito-
chondrial damage are demonstrable in MDS (63). In erythroid 
precursors from lower-risk MDS patients, mitochondria seques-
tration in the autophagosome is evident, indicating intrinsic 
differentiation defects and higher levels of dysfunctional, iron-
saturated mitochondria (64). This mitophagy defect generates 
ROS that contribute to DNA damage. A possible explanation may 
be that a basal level of autophagy in MDS occurs in response 
to oxidative stress to inhibit apoptosis induction. Alternatively, 
TLR4 activation alone can trigger autophagy by MyD99- and 
TRIF-induced dissociation of Beclin 1 from its inhibitor Bcl-2 
(65). To date, no mutations have been identified in autophagic 
machinery in MDS (17, 66). However, cytogenetic abnormalities 
localized in genes belonging to the autophagy network were 
identified in AML (67). Taken together, these data suggest a 
possible role for autophagy in MDS, and thus in transformation 
of MDS to AML. Autophagy and mitophagy could be beneficial 
to primary oncogene-mediated leukemic transformation and for 
the survival of neoplastic progenitors in a hostile milieu (67).
CONCLUSiON
Although the association of inflammation and chronic immune 
stimulation has long been associated with MDS, understanding 
the specific role in the underlying pathogenesis has only recently 
been recognized. TLR signaling and alterations in the BM micro-
environment, particularly MDSCs and their autocrine alarmin 
S100A9, sustain an inflammatory milieu that propagate the MDS 
clone. The pro-inflammatory environment coupled with genetic 
mutations and/or DAMP signals, activate inflammasomes and 
the induction of HSPC proliferation and pyroptosis within the 
MDS clone. More importantly, deciphering the key biological 
features of MDS has unveiled multiple potential strategies for 
future therapeutic intervention to improve outcomes for MDS 
patients.
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